SHAPE Trial and Its Impact on FIGO 2018 Cervical Cancer Staging and Treatment
The SHAPE trial demonstrated that simple total hysterectomy is non-inferior to radical hysterectomy for low-risk early-stage cervical cancer (FIGO 2018 stages IA2-IB1 ≤2 cm with stromal invasion <1 cm or <50%), with comparable 3-year pelvic recurrence rates (2.52% vs 2.17%) and significantly reduced urinary morbidity. 1, 2
What is the SHAPE Trial?
The SHAPE trial (AGO-OP.8 - CCTG CX.5) is a prospective randomized international multicenter study that compared simple total hysterectomy (experimental arm) versus radical hysterectomy (standard arm) in carefully selected patients with low-risk early-stage cervical cancer 1. This trial fundamentally challenges decades of surgical dogma that radical hysterectomy was necessary for all invasive cervical cancers.
Primary Conclusions and Clinical Implications
Eligibility Criteria (Critical for Patient Selection)
The trial specifically enrolled patients with:
- FIGO 2018 stages IA2 to IB1
- Tumor size ≤2 cm
- Stromal invasion depth <1 cm OR <50% stromal involvement 1, 3
Oncologic Outcomes
- Pelvic recurrence rate: 2.52% (simple hysterectomy) vs 2.17% (radical hysterectomy) - no statistically significant difference
- Recurrence-free survival: Non-inferior between groups
- Overall survival: Non-inferior between groups 1
Treatment Recommendation Based on SHAPE
For patients meeting SHAPE eligibility criteria, simple total hysterectomy may be considered as an alternative to radical hysterectomy on a case-by-case basis after appropriate patient counseling. 1 This represents a paradigm shift toward less radical surgery with reduced morbidity while maintaining oncologic safety.
Critical Caveats and Implementation Considerations
The MIS Controversy
A major pitfall: The SHAPE trial results do NOT address surgical approach (open vs minimally invasive). Recent data analyzing SHAPE-eligible patients from the KGOG 1028 cohort found that minimally invasive surgery (MIS) was associated with:
- Significantly shorter disease-free survival (55.4 vs 66.5 months, P=0.024)
- Higher pelvic recurrence rate (6.10% vs 1.88%, P=0.024)
- MIS identified as independent predictor of recurrence (HR 3.26) 4
This means that even in SHAPE-eligible low-risk patients, the surgical approach matters. The LACC trial concerns about MIS persist even in this favorable subset 2, 4.
Imaging Requirements in the Post-SHAPE Era
Radiologists must now provide structured MRI reports that specifically assess stromal invasion percentage, as this is a formal SHAPE eligibility criterion 3. Simply reporting tumor size and FIGO stage is insufficient. Required elements include:
- Tumor size
- Maximal depth of stromal invasion
- Estimated percentage of stromal involvement (<50% threshold)
- Outer stromal rim integrity
- Parametrial and vaginal status
- Distance to internal os 3
Current Guideline Position
The NCCN 2019 guidelines 5 were published before SHAPE results and still recommend:
- Radical hysterectomy with bilateral pelvic lymph node dissection as preferred treatment for FIGO stage IA2 through IIA1
- Simple/extrafascial hysterectomy only for IA1 disease
However, the AGO Uterus Commission statement acknowledges that simple total hysterectomy may be considered for FIGO IA2-IB1 ≤2 cm with infiltration depth <1 cm after suitable risk explanation, though they recommend waiting for full publication before establishing it as a new therapy standard 1.
Practical Algorithm for Decision-Making
Step 1: Confirm SHAPE Eligibility
- FIGO 2018 stage IA2-IB1
- Tumor ≤2 cm
- MRI-confirmed stromal invasion <50% or depth <1 cm
- No lymphovascular space invasion (implied by low-risk designation)
Step 2: If SHAPE-Eligible
- Option A: Simple total hysterectomy (with lymph node assessment)
- Option B: Radical hysterectomy (traditional standard)
- Critical: If choosing simple hysterectomy, strongly favor open approach over MIS given KGOG data 4
Step 3: If NOT SHAPE-Eligible
- Follow standard NCCN recommendations 5
- Radical hysterectomy with pelvic lymphadenectomy
- Consider sentinel lymph node mapping to reduce morbidity
Key Pitfall to Avoid
Do not extrapolate SHAPE results to patients outside the strict eligibility criteria. Tumors >2 cm, deeper stromal invasion, or higher-stage disease still require radical surgery or chemoradiation per established guidelines 5. The SHAPE trial's non-inferiority applies only to this highly selected low-risk population 1, 2.